EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: Investigation of significantly related factors on CT, FDG-PET, and histopathology
Received 9 May 2008; received in revised form 2 August 2008; accepted 4 August 2008. published online 26 September 2008.
Abstract
It has been suggested that a high EGFR gene copy number may be an indicator of good response to EGFR tyrosine kinase inhibitor therapy and a marker of poor prognosis in NSCLC. However, imaging features related to EGFR gene copy number status in adenocarcinoma are still unknown. We therefore retrospectively analyzed CT, FDG-PET, and histopathologic slides of surgical resected lung adenocarcinoma in 132 patients. Tumor characteristics on preoperative chest-CT, such as, GGO proportions, tumor diameters, and cavitation; FDG-PET SUVmax; and histopathologically determined differentiation degrees and tumor subtypes were evaluated. EGFR gene copy number status was categorized as FISH-positive or -negative. FISH-positivity was found in 53 patients (40.2%) and was significantly more frequent in tumors with a SUVmax>7.0 (P=0.007). Furthermore, FISH-negativity was found to be more frequent in tumors with a GGO>50% (P=0.023) and diameter <15.5mm (P=0.006) on CT, or a well-differentiated histopathology (P=0.002). Moreover, the frequency of FISH-positivity increased as SUVmax increased (P=0.0008) and as the proportion of GGO decreased (P=0.01). SUVmax>7.0 was an independent predictor of FISH-positive results (odds ratio, 3.941; 95% CI, 1.691–9.182; P=0.01). In conclusion, a high SUVmax on FDG-PET was significantly related to FISH-positive results. A high proportion of GGO, small tumor diameter on CT, and a well-differentiated histopathology were more frequent in FISH-negative adenocarcinomas.
aDepartment of Radiology, Seoul National University Hospital, 28 Yeongeon-dong, Chongno-gu, Seoul 110-744, Republic of Korea
bDepartment of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Cancer Research Institute, Xenotransplantation Research Center, Clinical Research Center, Seoul National University College of Medicine, 28 Yeongeon-dong, Jongno-gu, Seoul 110-744, Republic of Korea
cDepartment of Nuclear Medicine, Seoul National University Hospital, 28 Yeongeon-dong, Chongno-gu, Seoul 110-744, Republic of Korea
dDepartment of Pathology, Seoul National University Hospital, 28 Yeongeon-dong, Chongno-gu, Seoul 110-744, Republic of Korea
Corresponding author at: Department of Radiology, Seoul National University Hospital, 28 Yongon-dong, Chongno-gu, Seoul 110-799, Republic of Korea. Tel.: +82 2 2072 2584/1861; fax: +82 2 743 6385.